Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LABT vs PFSA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PFSA Wins Head-to-Head Institutional Verdict (2–0 across 6 Pillars · 7–0 Matrix Metrics)

PFSA Overall Winner 6-Pillar Tally: LABT 0 – 2 PFSA (4 Tie) Matrix Metrics: LABT 0 – 7 PFSA

As of Nov 20, 2026, Profusa, Inc. (PFSA) is the stronger overall head-to-head candidate over LABT (LABT) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 2–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). LABT carries a Unified Composite Score of 47.5/100 (HOLD) at $0.24 (N/M Forward P/E, N/A operating margin), whereas PFSA carries 48.7/100 (HOLD) at $0.32 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: LABT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile PFSA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LABT vs PFSA
LABT US Equity
LABT
Institutional Equity
$0.24
+15.03% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -8.45β · 672% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -49.4%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $0.29 · SMA50: $0.80
PFSA NASDAQ Head-to-Head Winner
Profusa, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.32
-6.4% 1D
Market Cap $2.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.00β · 92% Vol
Unified Composite Score
48.7 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -60.9%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $0.56 · SMA50: $1.20

6-Pillar Scorecard Institutional Category Breakdown (LABT 0 – 2 PFSA)

Columns: Metric · LABT · PFSA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PFSA
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $2.0M
3. Profitability & Quality PFSA
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A 0.0%
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE 0.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LABT (0) vs PFSA (7)
Institutional Metric LABT PFSA Criterion Row Edge
Market Capitalization
Scale
N/A $2.0M Larger Scale PFSA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth PFSA
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin PFSA
Net Profit Margin
Profitability
N/A 0.0% Higher Margin PFSA
Return on Equity (ROE)
Capital Efficiency
N/A 0.0% Higher ROE PFSA
52-Week Range Position
Momentum
1% ($0–$10) 1% ($0–$28) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
-8.45β · 672% Vol -9.00β · 92% Vol Lower Realized Risk PFSA
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 48.7 / 100 (HOLD) Higher Composite PFSA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (0.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LABT +18.32 pp
LABT: -49.97% · PFSA: -68.29%
3M Horizon LABT +4.44 pp
LABT: -88.5% · PFSA: -92.94%
6M Horizon PFSA +51.3 pp
LABT: -65.34% · PFSA: -14.04%
1Y Horizon PFSA +51.47 pp
LABT: -97.17% · PFSA: -45.7%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LABT vs PFSA. Trailing 12-month operating profitability (LABT N/A vs PFSA 0.0%) and valuation multiples (LABT N/M vs PFSA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LABT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
PFSA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LABT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LABT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PFSA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PFSA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LABT Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PFSA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LABT vs PFSA Key Questions & Quantitative Answers

As of Nov 20, 2026, Profusa, Inc. (PFSA) is the stronger overall head-to-head candidate over LABT (LABT) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 2–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). LABT carries a Unified Composite Score of 47.5/100 (HOLD) at $0.24 (N/M Forward P/E, N/A operating margin), whereas PFSA carries 48.7/100 (HOLD) at $0.32 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: LABT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile PFSA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PFSA leads the Growth & Scale pillar: LABT posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with PFSA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LABT generates N/A in USD-normalized revenue versus N/A for PFSA. In operating R&D and SG&A reinvestment, LABT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PFSA.

LABT and PFSA trade at balanced relative valuation multiples. LABT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PFSA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LABT (N/A ROE) versus PFSA (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, LABT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-8.45β · 672% Vol realized risk). By comparison, PFSA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.00β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.